Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321653 | Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes(AXILL-ART) | recruiting | — | 120 | European Institute of OncologyOTHER | 1 |
| Mar 20, 2024 |
| clinicaltrials |
| NCT06227117 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | recruiting | Phase 2 | 120 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06319157 | Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction | recruiting | N/A | 94 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06315868 | Breast Cancer Subtype Characterization Through Patient's Derived Organoids.(BCinsightPDO) | recruiting | — | 306 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06313463 | Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy | recruiting | Phase 3 | 375 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06202261 | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 154 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05789901 | The MARVIN Chatbots to Provide Information for Different Health Conditions | recruiting | N/A | 400 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06286267 | AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors | recruiting | — | 4,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281145 | Stress-Reducing Intervention in Patients With Colorectal and Breast Cancer(SRI-BrCa_CRC) | recruiting | N/A | 100 | Comenius UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281210 | Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery(BETTY-CRASY) | recruiting | N/A | 77 | European Institute of OncologyOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06282796 | Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy | recruiting | — | 600 | First Hospital of China Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06266026 | ThermoBreast - Non-contact Breast Cancer Imaging Using AI-enhanced Thermography.(ThermoBreast) | recruiting | N/A | 28,000 | ThermoMind Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06268652 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | recruiting | Phase 3 | 302 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06259162 | LAG3 Expression in Triple Negative Breast Cancer | recruiting | N/A | 128 | Samsung Medical CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06259513 | Omission of Axillary Surgery in Breast Cancer Patients | recruiting | N/A | 350 | KK Women's and Children's HospitalOTHER_GOV | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06254690 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | recruiting | Phase 2 | 102 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05891093 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | recruiting | Phase 3 | 766 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05949541 | Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer(BCTOP-L-M01) | recruiting | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT02839863 | Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation - The UMBRELLA Cohort(UMBRELLA) | recruiting | — | 10,000 | UMC UtrechtOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | recruiting | Phase 3 | 372 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06235931 | A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC | recruiting | N/A | 34 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06169072 | Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients(MagSnow2) | recruiting | Phase 2 | 220 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06162559 | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study(TRAIN-4) | recruiting | Phase 1 | 30 | The Netherlands Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06165900 | Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC | recruiting | Phase 2 | 136 | Shengjing HospitalOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06185569 | FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy(FREDO-ODX-23) | recruiting | — | 4,500 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04050228 | Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer | recruiting | N/A | 240 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06001086 | A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer | recruiting | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05689619 | SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)(SILMET) | recruiting | N/A | 70 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04050423 | Investigation of Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses | recruiting | — | 1,200 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04134780 | Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response | recruiting | — | 150 | Sunnybrook Health Sciences CentreOTHER | 2 | Dec 14, 2023 | clinicaltrials |
| NCT04428528 | Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy | recruiting | — | 100 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT00437879 | Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment. | recruiting | — | 600 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05978648 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy(SMA-BC-002) | recruiting | Phase 2 | 116 | wang shusenOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06144346 | Metastases Directed Therapy for Oligometastatic Breast Cancer | recruiting | N/A | 150 | National Cancer Institute, EgyptOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06093022 | Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study(SurMed-BCLM) | recruiting | — | 720 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121557 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121570 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06104085 | 99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06090747 | Improving Lifestyle Behavior by "Joven, Fuerte y Saludable" Multidisciplinary Program. | recruiting | N/A | 146 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04925856 | Immunomonitoring of Breast Cancer Patients During Systemic Treatment(IMMUNE CAPTURE) | recruiting | N/A | 150 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04687956 | Primary Surgical Prevention of Breast Cancer-related Lymphedema(LYMPHA) | recruiting | N/A | 72 | Gangnam Severance HospitalOTHER | 1 | Oct 11, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 21, 2024source: clinicaltrials